Clarity Pharmaceuticals Ltd

Company Profile

• Business description

  Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.

• Contact

  2-4 Cornwallis Street
  Suite 212a, National Innovation Centre
  Eveleigh
  SydneyNSW2015
  AUS

  T: +61 292094037

  https://www.claritypharmaceuticals.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  30 June 2027

  Employees

  70